Campbell & CO Investment Adviser LLC Raises Stock Holdings in argenex SE $ARGX

Campbell & CO Investment Adviser LLC lifted its holdings in shares of argenex SE (NASDAQ:ARGX) by 137.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,535 shares of the company’s stock after acquiring an additional 3,207 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in argenex were worth $3,051,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ARGX. Lord Abbett & CO. LLC boosted its stake in argenex by 33.2% during the 1st quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock worth $162,585,000 after purchasing an additional 68,498 shares during the period. Millennium Management LLC raised its holdings in shares of argenex by 316.9% in the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after buying an additional 204,180 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of argenex by 6.1% during the second quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock worth $145,879,000 after buying an additional 15,186 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of argenex by 4.8% during the second quarter. Allspring Global Investments Holdings LLC now owns 184,987 shares of the company’s stock worth $100,350,000 after buying an additional 8,537 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of argenex by 14.8% during the first quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock worth $99,886,000 after buying an additional 21,805 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ARGX shares. Bank of America increased their price objective on argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. increased their price target on argenex from $830.00 to $925.00 and gave the stock an “overweight” rating in a report on Friday. TD Cowen boosted their price objective on shares of argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Piper Sandler upped their price objective on shares of argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, Royal Bank Of Canada lifted their target price on shares of argenex from $850.00 to $860.00 and gave the company an “outperform” rating in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, argenex has a consensus rating of “Moderate Buy” and an average target price of $869.68.

argenex Stock Up 0.4%

NASDAQ:ARGX opened at $854.65 on Monday. The firm’s fifty day simple moving average is $782.86 and its 200-day simple moving average is $663.39. The stock has a market cap of $52.62 billion, a PE ratio of 36.70, a price-to-earnings-growth ratio of 0.89 and a beta of 0.45. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $857.48.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Equities analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.